NSAIDs and aminoglycosides should be avoided in patients with CKD because they are nephrotoxic.
Although both numbers are important, systolic blood pressure control is considered more important than diastolic blood pressure control. Aggressive blood pressure control can help to delay the decline in renal function in patients with CKD. The 2021 European Society of Cardiology guidelines suggest a target blood pressure of < 130/80 mm Hg.
Data support the use of ACEIs or ARBs in diabetic kidney disease with or without albuminuria. In nondiabetic kidney disease, these agents are effective in retarding the progression of disease among patients with proteinuria of > 500 mg/dL.
Many patients with CKD are vitamin D deficient, which contributes to the development of CKD, mineral bone disease. Two synthetic vitamin D analogues are approved by the US Food and Drug Administration. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with CKD stages III-V. Calcifediol is indicated for secondary hyperparathyroidism associated with vitamin D insufficiency in patients with stage III or IV CKD. The effect of vitamin D supplementation on clinical outcomes is not yet certain.
Learn more about the management of CKD.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Vecihi Batuman, Patrick Rossignol. Fast Five Quiz: Is Your Knowledge of Chronic Kidney Disease Sufficient? - Medscape - Jul 21, 2022.